Market revenue in 2023 | USD 12.2 million |
Market revenue in 2030 | USD 24.5 million |
Growth rate | 10.4% (CAGR from 2023 to 2030) |
Largest segment | Mrna reprogramming |
Fastest growing segment | MRNA Reprogramming |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Sendai Virus-based Reprogramming, MRNA Reprogramming, Episomal Reprogramming |
Key market players worldwide | Thermo Fisher Scientific Inc, Merck KGaA, Bio-Techne Corp, ReproCELL, Lonza Group Ltd, FUJIFILM Holdings Corp, Astellas Pharma Inc, Allele Biotech, Alstem, STEMCELL Technologies |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cell reprogramming market will help companies and investors design strategic landscapes.
Mrna reprogramming was the largest segment with a revenue share of 33.61% in 2023. Horizon Databook has segmented the Canada cell reprogramming market based on sendai virus-based reprogramming, mrna reprogramming, episomal reprogramming covering the revenue growth of each sub-segment from 2018 to 2030.
The cell reprogramming market in Canada is expected to exhibit significant growth over the forecast period due to the ongoing expansion of manufacturing facilities by key players in the market. The presence of local players, such as STEMCELL Technologies, Aspect Biosystems, and Blue Rock Therapeutics, is a key factor boosting the market in Canada.
For instance, in November 2021, Aspect Biosystems, a Canada-based biotechnology company, entered into an agreement with the University Health Network (UHN). This collaboration aimed to integrate Aspect Biosystems' advanced bioprinting technology with UHN's stem cell differentiation protocols.
The primary objective was to advance the development of bioprinted cell therapies targeting various genetic and acquired liver diseases. The agreement also allowed Aspect Biosystems to commercialize the technology and methodologies associated with differentiating stem cells into hepatocytes.
Horizon Databook provides a detailed overview of country-level data and insights on the Canada cell reprogramming market , including forecasts for subscribers. This country databook contains high-level insights into Canada cell reprogramming market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account